Trial · NCT05705089
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
NCT05705089, Phase 3, Completed, Rajaie Cardiovascular Medical and Research Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI. Trials, record NCT05705089. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05705089
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
- NCT number
- NCT05705089
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 50 participants, actual
- Lead sponsor
- Rajaie Cardiovascular Medical and Research Center
- Conditions
- Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction
- Interventions
- Rivaroxaban 15 MG, Warfarin
- First posted
- 2023-01-30
- Last updated
- 2023-04-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resolution of left ventricular thrombus | at 3 months from enrollment | Resolution of left ventricular thrombus according to non-contrast 2D TTE performed by the imaging core laboratory, blinded to the allocation assignment |
| Other | The proportion of patients with adjudicated stroke and systemic emboli | At 3 months from enrollment | Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction. Systemic emboli are defined as any acute non-cerebral embolic events with a cardiac origin. |
| Other | The proportion of patients with adjudicated major adverse cardiac events (MACE) | At 3 months from enrollment | A composite of death from cardiovascular causes, myocardial infarction, or stroke. |
| Other | The proportion of patients with adjudicated all-cause death | At 3 months from enrollment | All-cause death is defined as a composite of cardiovascular, non-cardiovascular and undetermined cause of death. |
| Other | Left ventricular thrombus resolution percentage | At 3 months from enrollment | Left ventricular thrombus resolution percentage according to non-contrast 2D TTE performed by the imaging core laboratory, blinded to the allocation assignment |
| Other | The proportion of patients with adjudicated major bleeding events | At 3 months from enrollment | Adjudicated based on International Society on Thrombosis and Hemostasis (ISTH) definition |
| Other | The proportion of patients with adjudicated clinically relevant not major bleeding events | At 3 months from enrollment | Adjudicated based on International Society on Thrombosis and Hemostasis (ISTH) definition |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39773831 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05705089
GET https://conductscience.org/api/trials/v1/NCT05705089/registered